Park, Min
Nishimura, Takanori
Baeza-Garza, Carlos D.
Caldwell, Stuart T.
Pun, Pamela Boon Li
Prag, Hiran A.
Young, Tim
Sauchanka, Olga
Logan, Angela
Forkink, Marleen
Gruszczyk, Anja V.
Prime, Tracy A.
Arndt, Sabine
Naudi, Alba
Pamplona, Reinald
Coughlan, Melinda T.
Tate, Mitchel
Ritchie, Rebecca H.
Caicci, Federico
Kaludercic, Nina
Di Lisa, Fabio
Smith, Robin A. J.
Hartley, Richard C.
Murphy, Michael P.
Krieg, Thomas http://orcid.org/0000-0002-5192-580X
Funding for this research was provided by:
British Heart Foundation (PG/15/84/31670)
Consejo National de Ciencia y Technologia (n/a)
Medical Research Council (MC_U105663142)
Wellcome Trust (110159/Z/15/Z)
Biotechnology and Biological Sciences Research Council (BB/I012826/1)
Wellcome Trust (110158/Z/15/Z)
National Health and Medical Research Council (APP1059960)
Generalitat of Catalonia (SLT002/16/00250)
Department of Business and Knowledge (2017SGR696)
Article History
Accepted: 17 September 2020
First Online: 26 September 2020
Compliance with Ethical Standards
:
: MPM, RAJS and RCH are inventors on a patent that includes MitoGamide: mitochondria-targeted dicarbonyl sequestering compounds. Murphy, M. P.; Smith, R. A. J.; Hartley, R. C. WO 2015075200. A1.
: All animal experiments were carried out in accordance with the UK Home Office Guide on the Operation of Animals (Scientific Procedures) Act of 1986 and approved under the project licence number PPL 70/8239.